- Home
- REE vs LPCN Comparison
REE vs LPCN Comparison
Compare REE & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- LPCN
- Stock Information
- Founded
- REE 2011
- LPCN 1997
- Country
- REE Israel
- LPCN United States
- Employees
- REE N/A
- LPCN N/A
- Industry
- REE Auto Manufacturing
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- LPCN Health Care
- Exchange
- REE Nasdaq
- LPCN Nasdaq
- Market Cap
- REE 22.4M
- LPCN 18.2M
- IPO Year
- REE N/A
- LPCN N/A
- Fundamental
- Price
- REE $0.86
- LPCN $2.60
- Analyst Decision
- REE Strong Buy
- LPCN Strong Buy
- Analyst Count
- REE 2
- LPCN 1
- Target Price
- REE $11.75
- LPCN $8.00
- AVG Volume (30 Days)
- REE 1.1M
- LPCN 33.9K
- Earning Date
- REE 12-16-2025
- LPCN 11-06-2025
- Dividend Yield
- REE N/A
- LPCN N/A
- EPS Growth
- REE N/A
- LPCN N/A
- EPS
- REE N/A
- LPCN N/A
- Revenue
- REE $183,000.00
- LPCN $4,208,119.00
- Revenue This Year
- REE $327.73
- LPCN N/A
- Revenue Next Year
- REE $36,888.82
- LPCN N/A
- P/E Ratio
- REE N/A
- LPCN N/A
- Revenue Growth
- REE N/A
- LPCN N/A
- 52 Week Low
- REE $0.53
- LPCN $2.52
- 52 Week High
- REE $11.72
- LPCN $6.16
- Technical
- Relative Strength Index (RSI)
- REE 39.10
- LPCN 37.33
- Support Level
- REE $1.06
- LPCN $2.52
- Resistance Level
- REE $1.10
- LPCN $2.92
- Average True Range (ATR)
- REE 0.12
- LPCN 0.14
- MACD
- REE -0.05
- LPCN -0.03
- Stochastic Oscillator
- REE 0.03
- LPCN 14.30
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.